These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
185 related articles for article (PubMed ID: 29204314)
21. Clinical profile of botulinum toxin A in patients with chronic headaches and cervical dystonia: a prospective, open-label, longitudinal study conducted in a naturalistic clinical practice setting. Dowson AJ; Kilminster SG; Salt R Drugs R D; 2008; 9(3):147-58. PubMed ID: 18457467 [TBL] [Abstract][Full Text] [Related]
22. Is Botulinum Toxin Type A Efficacious, Safe, and Tolerable in Cervical Dystonia?: A Cochrane Review Summary With Commentary. Oral A Am J Phys Med Rehabil; 2020 Jul; 99(7):649-651. PubMed ID: 32251106 [No Abstract] [Full Text] [Related]
23. Dynamic balance function in phasic cervical dystonia following Botulinum toxin therapy. Müller J; Ebersbach G; Wissel J; Poewe W Mov Disord; 2001 Sep; 16(5):934-7. PubMed ID: 11746626 [TBL] [Abstract][Full Text] [Related]
24. Reply: Botulinum toxin type B vs. type A in toxin-naïve patients with cervical dystonia: randomized, double-blind, noninferiority trial. Mueller J Mov Disord; 2009 May; 24(7):1098-9; author reply 1100. PubMed ID: 18942082 [No Abstract] [Full Text] [Related]
25. Personalized botulinum toxin type A therapy for cervical dystonia based on kinematic guidance. Samotus O; Lee J; Jog M J Neurol; 2018 Jun; 265(6):1269-1278. PubMed ID: 29557988 [TBL] [Abstract][Full Text] [Related]
26. Botulinum toxin type B vs. type A in toxin-naïve patients with cervical dystonia: Randomized, double-blind, noninferiority trial. Pappert EJ; Germanson T; Mov Disord; 2008 Mar; 23(4):510-7. PubMed ID: 18098274 [TBL] [Abstract][Full Text] [Related]
27. Brain connectivity abnormalities and treatment-induced restorations in patients with cervical dystonia. Feng L; Yin D; Wang X; Xu Y; Xiang Y; Teng F; Pan Y; Zhang X; Su J; Wang Z; Jin L Eur J Neurol; 2021 May; 28(5):1537-1547. PubMed ID: 33350546 [TBL] [Abstract][Full Text] [Related]
29. Cost-utility analysis of botulinum toxin type A products for the treatment of cervical dystonia. Kazerooni R; Broadhead C Am J Health Syst Pharm; 2015 Feb; 72(4):301-7. PubMed ID: 25631837 [TBL] [Abstract][Full Text] [Related]
30. Somatosensory cortical activation in cervical dystonia and its modulation with botulinum toxin: an fMRI study. Opavský R; Hluštík P; Otruba P; Kaňovský P Int J Neurosci; 2012 Jan; 122(1):45-52. PubMed ID: 21919815 [TBL] [Abstract][Full Text] [Related]
31. Comparison of botulinum neurotoxin preparations for the treatment of cervical dystonia. Chapman MA; Barron R; Tanis DC; Gill CE; Charles PD Clin Ther; 2007 Jul; 29(7):1325-37. PubMed ID: 17825685 [TBL] [Abstract][Full Text] [Related]
32. The Impact of the Course of Disease before Botulinum Toxin Therapy on the Course of Treatment and Long-Term Outcome in Cervical Dystonia. Hefter H; Schomaecker I; Schomaecker M; Rosenthal D; Samadzadeh S Toxins (Basel); 2021 Jul; 13(7):. PubMed ID: 34357965 [TBL] [Abstract][Full Text] [Related]
33. Tremor in Idiopathic Cervical Dystonia - Possible Implications for Botulinum Toxin Treatment Considering the Col-Cap Classification. Pandey S; Kreisler A; Drużdż A; Biering-Sørensen B; Sławek J; Tatu L; Jost WH Tremor Other Hyperkinet Mov (N Y); 2020 Jul; 10():13. PubMed ID: 32775027 [TBL] [Abstract][Full Text] [Related]
34. Botulinum toxin type A and cervical dystonia: a seven-year follow-up. Camargo CH; Teive HA; Becker N; Munhoz RP; Werneck LC Arq Neuropsiquiatr; 2011 Oct; 69(5):745-50. PubMed ID: 22042174 [TBL] [Abstract][Full Text] [Related]
35. Botulinum toxin type A versus anticholinergics for cervical dystonia. Costa J; Espírito-Santo C; Borges A; Ferreira JJ; Coelho M; Sampaio C Cochrane Database Syst Rev; 2005 Jan; 2005(1):CD004312. PubMed ID: 15674939 [TBL] [Abstract][Full Text] [Related]